A new framework reveals Alzheimer's disease is far more complex than previously believed. Rather than being a disease where the same causes produce the same outcomes, researchers found three different models for the disease, each with its own characterizations and dynamics.
Older adults who sleep less than 4.5 hours, or more than 6.5 hours per night and who experience sleep disruptions are at greater risk of cognitive decline, researchers report.
Inhibiting the NHE6 gene abolished the formation of amyloid-beta plaques in mouse models of Alzheimer's disease.
New findings contradict the existing thought that Alzheimer's starts from a single point in the brain and causes a chain reaction that leads to cell death. Instead, a new study reports, Alzheimer's disease reaches different brain regions early on. The speed by which the disease kills brain cells in these regions directly impacts the progression of Alzheimer's.
PET study finds early accumulation of the tau protein in the brain is a better predictor of Alzheimer's associated memory decline than amyloid plaque accumulation or cerebrospinal fluid biomarkers.
Study identifies specific chemical features of tau that may cause it to accumulate in the brain and trigger Alzheimer's disease.
Gantenerumab, an investigational drug for Alzheimer's disease, reduced amyloid plaques and lowered tau levels in the brains of people with genetic risk factors for the neurodegenerative disorder.
Elderly monkeys treated with CpG ODN had 59% fewer deposits of Alzheimer's related plaques in their brains compared to those who did not receive the treatment. The treatment also helped improve cognitive function and slow the progression of Alzheimer's symptoms.